Clinical Studies

Clinical studies  are the cornerstone of medical knowledge. By taking part in clinical research, patients get the opportunity to improve their own health while impacting the care of others.

The Primary Aldosteronism Foundation fosters research worldwide, and encourages everyone in the PA patient community to participate in clinical research. Below is the list of all clinical studies referenced by under primary aldosteronism. The list includes all published studies and is updated as soon as they are made public. Click on the title of any study to be taken to a web page with full details on the US National Library of Medicine website.

Trial Status:

Search by Keyword:


This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agent injection.

Status: Recruiting     Trial Number: NCT04328181  
Conditions: 12 conditions including adrenal gland lesions and primary aldosteronism
Interventions: Device: Spectral Photon Counting Computed Tomography (SPCCT); Device: DECT (Dual Energy CT)
Locations: Hopital Cardioloqiue Louis Pradel – Hospices Civils de Lyon. Lyon, France


Although it has been investigated that the main cause of APA or UAH is the mutations of different calcium ion channels, including KCNJ5, CACNA1D, CLCN2 et al, it is still unknown whether there are any other changes of other proteins in different layers. Therefore, the investigators designed the study to characterize the proteomics profiles of adrenal adenoma/hyperplasia leading to primary aldosterone and identify biomarkers for early identification of PA by using spatial proteomics. The samples from adrenal adenoma or hyperplasia will be collected and analyzed by spatial proteomics in Hangzhou Jingjie Biotechnology Co., Ltd.

Status: Not yet recruiting     Trial Number: NCT05927961  
Conditions: Primary aldosteronism
Interventions: Diagnostic Test: histopathology
Locations: The Third Affiliated Hospital of the Third Military Medical University, Chongqing, China


The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

Status: Unknown     Trial Number: NCT04278404  
Conditions: More than 25 conditions including hypertension and primary aldosteronism
Interventions: Drug: This study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Locations: Phoenix Children’s Hospital, Phoenix, AZ; Arkansas Children’s Hospital Research Institute, Little Rock, AR; University of California, Los Angeles, CA; Lucile Packard Children’s Hospital, Palo Alto, CA; Colorado University Denver, Aurora, CO; DuPont Hospital for Children, Wilmington, DE; Jacksonville Shands Medical Center, Jacksonville, FL; Kapiolani Womens and Childrens Medical Center, Honolulu, HI; Ann and Robert Lurie Childrens Hospital of Chicago, Chicago, IL; Riley Hospital for Children at Indiana University, Indianapolis, IN; University of Iowa Stead Family Children’s Hospital, Iowa City, IA; University of Louisville Norton Childrens Hospital, Louisville, KY; Ochsner Baptist Clinical Trials Unit, New Orleans, LA; University of Maryland Medical Center, Baltimore, MD; Boston Children’s Hospital, Boston, MA; Massachusetts General Hospital, Lexington, MA; University of Minnesota, Minneapolis, MN; University of Mississippi, Jackson, MS; Mississippi Center for Advanced Medicine, Madison, MS; Childrens Mercy Hospital, Kansas City, MO; University of Nebraska Medical Center, Omaha, NE; University of New Mexico Health Science Center, Albuquerque, NM; University of North Carolina, Chapel Hill, NC; Durham University Health System, Durham, NC; Cincinnati Childrens Hospital Medical Center, Cincinnati, OH; Board of Regents of the University of Oklahoma, Oklahoma City, OK; Oregon Health and Science University, Portland, OR; Hershey Children’s Hospital, Hershey, PA; Medical University of South Carolina, Charleston, SC; University of South Carolina, Columbia, SC; Avera McKennan Hospital & University Medical Center, Sioux Falls, SD; Children’s Hospital at Vanderbilt, Nashville, TN; Dell Children’s Medical Center of Central Texas, Austin, TX; University of Texas-Southwestern Medical Center, Dallas, TX; University of Texas – Memorial Hermann Texas Medical Center, Houston, TX; Seattle Children’s Hospital, Seattle, WA; West Virginia University Hospital, Morgantown, WV; University of Wisconsin, Madison, WI; Medical Center of Wisconsin, Milwaukee, WI; Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada; The Hospital for Sick Children, Toronto, Ontario, Canada; CHU Sainte-Justine, Montreal, Quebec, Canada


The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home – Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

Status: Recruiting     Trial Number: NCT06065852  
Conditions: More than 80 conditions including primary aldosteronism
Interventions: Observational
Locations: UK Kidney Association, Bristol, South West, UK


Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies. A higher prevalence of thyroid nodules and non-toxic multinodular goiter was described in patients with PA compared to those with essential hypertension (EH). A single study showed an association between PA and papillary thyroid cancer (PTC), but without a paired control group. Objective: To assess PA prevalence in a transversal cohort of patients with PTC and EH compared to a paired control group with HT.

Status: Completed     Trial Number: NCT06068101  
Conditions: Primary aldosteronism, Thyroid cancer (papillary)
Interventions: Diagnostic Test: Screening test for primary aldosteronism and confirmatory Testing
Locations: Instituto do Cancer do Estado de São Paulo, Sao Paulo, Brazil


Endocrine diseases including Cushing’s syndrome and phaeochromocytoma/paraganglioma (PPGL) but not Conn’s syndrome are associated with muscle wasting and weakness. The study’s aim is to identify epigenetic determinants of muscle homeostasis in these conditions following medical treatment and adrenalectomy.

Status: Terminated     Trial Number: NCT05456997  
Conditions: Cushing’s Syndrome, Pheochromocytoma, Conn’s Syndrome, Metabolic Myopathy
Interventions: Procedure: Muscle biopsy
Locations: Barts Heart Centre, London, UK